CN105287535A - Anti-diabetes oral pharmaceutical composition - Google Patents
Anti-diabetes oral pharmaceutical composition Download PDFInfo
- Publication number
- CN105287535A CN105287535A CN201510766787.7A CN201510766787A CN105287535A CN 105287535 A CN105287535 A CN 105287535A CN 201510766787 A CN201510766787 A CN 201510766787A CN 105287535 A CN105287535 A CN 105287535A
- Authority
- CN
- China
- Prior art keywords
- base
- methoxynaphthalene
- diabetes
- pharmaceutical composition
- biphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an anti-diabetes oral pharmaceutical composition. The anti-diabetes oral pharmaceutical composition comprises the following components: 1) 10-20 mg of 5-(3-hydroxy-7-methoxynaphthalene-2-yl)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt, 2) 20-30 mg of 3-(2-(2',6 '-dimethyl-[1,1'-biphenyl]-3-yl)chroman-6-yl)propionic acid, 3)200-300 mg of microcrystalline cellulose, 4) 10-25 mg of cross linked sodium carboxymethyl cellulose, and 5) 1-8 mg of magnesium stearate. By complex formulation of two different types of active matters, under prerequisite that treatment effect is same, the application amount of the active matter of the medicine is reduced by at least 1/2.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of diabetes combination of oral medication.
Background technology
The metabolic disease of diabetes to be one group with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological agent impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.
The generally acknowledged form of usual existence two kinds of diabetes.In type 1 diabetes or insulin-dependent diabetes (IDDM), patient produces seldom or does not have insulin, regulates the hormone of glucose application.In type 2 diabetes mellitus or noninsulindependent diabetes (NIDDM), still produce insulin in the body.There is in the stimulation glucose of the patient suffering from type 2 diabetes mellitus in main insulin-sensitive tissue (it is muscle, liver and fatty tissue) and lipid metabolism the toleration to insulin action.These patients have the insulin of common level usually, and may have hyperinsulinemia (plasma insulin level of rising), because they compensate by the insulin of secretion rise the insulin effects reduced.Insulin resistance can not be caused by the Insulin receptor INSR reducing quantity but be caused by the rear Insulin receptor INSR binding deficient understood not yet completely substantially.This lacks and to cause in the oxidation of glucose in the activation of the insulin-mediated of inadequate picked-up, muscle and storage and fatty tissue glucose in lipidolysis and liver to produce to the responding ability of insulin and the suppression of insufficient insulin-mediated of secretion.
Current Remedies for diabetes is maintaining treatment effect, many employing 100mg active matter oral doses, and needs daily repeatedly to take.Due to the side effect of active matter, other health hazards are caused to patient, meanwhile, due to the increase of dosage, also make medicine cost increase, cause the raising for the treatment of cost.
Summary of the invention
The object of the invention is to propose a kind of diabetes combination of oral medication, its composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2.
For reaching this object, the present invention by the following technical solutions:
A kind of diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 3-(2-(2', 6'-dimethyl-[1,1'-the biphenyl]-3-base) chromane-6-base) propanoic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
Described 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt and 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) ratio of propanoic acid is less than in 1.
Detailed description of the invention
The present invention is described pharmaceutical composition of the present invention by following embodiment.
Embodiment 1
I.5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
Step 1
3-benzyloxy-7-methoxynaphthalene-2-benzyl formate
5.0g (21.7mmol) 3-hydroxyl-7-methoxynaphthalene-2-formic acid, 9.29g (54.3mmol) benzyl bromide a-bromotoluene and the mixture of 9.01g (65.2mmol) potassium carbonate in 25mLDMF are stirred 24 hours in 60 DEG C.After being cooled to room temperature, by mixture impouring water, be extracted in EtOAc.Organic facies is washed with 3 × water and 1 × saturated NaCl.Use dried over sodium sulfate organic facies, under reduced pressure except desolventizing.Making residual solid crystallization from dichloromethane/ethanol, obtain title compound, is Tan solid, mp96-98 °.
H-NMR (CDCl): δ 8.25 (s, 1H), 7.61 (d, J=8.83Hz, 1H), 7.49 (d, J=7.35Hz, 2H), 7.46-7.30 (m, 7H), 7.24 (d, J=5.88Hz, 2H), 7.18 (dd, J=9.20 and 2.58Hz, 1H), 7.12 (m, 1H), 5.40 (s, 2H), 5.23 (s, 2H), 3.89 (s, 3H). analyze: CHO: value of calculation C, 78.38; H, 5.57. measured value C, 78.28; H, 5.56.
Step 2
3-benzyloxy-7-methoxynaphthalene-2-formic acid
In the suspension of 6.07g (20mmol) 3-benzyloxy-7-methoxynaphthalene-2-benzyl formate in 100mL ethanol, add 24mL1.0NNaOH (1.2 equivalent), mixture is stirred 4 hours in 60 DEG C, in stirring at room temperature 16 hours.Under reduced pressure except desolventizing, residual solid is dissolved in 50mL water.Use washed with diethylether solution, with 2NHCl acidify aqueous phase.Filtration gained precipitates, and washes with water, and dry, obtaining title compound, is faint yellow solid.
Mp177-179 ° of .H-NMR (CDCl): δ 11.01 (s, wide, 1H), 8.70 (s, 1H), 7.67 (d, J=8.82Hz, 1H), 7.53-7.41 (m, 5H), 7.37 (s, 1H), 7.27 (dd, J=8.83 and 2.57Hz, 1H), 7.20 (m, 1H), 5.36 (s, 2H), 3.92 (s, 3H). analyze: CHO: value of calculation C, 74.01; H, 5.23. measured value C, 73.71; H, 5.46.
Step 3
(3-benzyloxy-7-methoxynaphthalene-2-base)-t-butyl carbamate
In the suspension of the anhydrous t-BuOH+40mL dry toluene of 40mL, 2.3g (22mmol) triethylamine is added to 4.6g (14.9mmol) 3-benzyloxy-7-methoxynaphthalene-2-formic acid.In gained solution, add 5.34g (19.4mmol) DPPA, by mixture in stirring at room temperature 5 minutes, then stir 18 hours in 100 DEG C.Mixture is cooled to room temperature, then in impouring water.Mixture extraction is entered in EtOAc, wash organic facies with saturated NaCl.Under reduced pressure except desolventizing, residue uses hexane/ethyl acetate (85: 15) to carry out purification by flash chromatography, elutes title compound, is grease, slowly becomes waxy solid.
H-NMR(CDCl)：δ8.48(s，1H)，7.50(d，J＝8.82Hz，1H)，7.48-7.31(m，7H)，7.10(s，1H)，6.99(dd，J＝8.82and2.57Hz，1H)，5.17(s，2H)，3.84(s，3H)，1.54(s，9H).
Step 4
3-benzyloxy-7-methoxynaphthalene-2-base amine
By 4.99g (13.1mmol) (3-benzyloxy-7-methoxynaphthalene-2-base) solution of-t-butyl carbamate in 50mLTFA/ dichloromethane (1: 1) in stirring at room temperature 30 minutes.Under reduced pressure except desolventizing, 10% sodium bicarbonate aqueous solution is joined in residue.Mixture extraction is entered in EtOAc, use dried over sodium sulfate organic facies.Under reduced pressure except desolventizing, residue uses dichloromethane to carry out purification by flash chromatography, elutes title compound, makes its crystallization from ethanol, obtain white solid,
Mp149-151 ° of .H-NMR (CDCl): δ 7.54-7.32 (m, 6H), 7.09 (s, 1H), 6.92 (d, J=9.20Hz, 2H), 6.89 (dd, J=8.82 and 2.57Hz, 1H), 5.18 (s, 2H), 4.11 (s, wide, 2H), (3.87 s, 3H).
Step 5
(3-benzyloxy-7-methoxynaphthalene-2-base is amino)-methyl acetate
2.26g (14.8mmol) methyl bromoacetate is added in 2.76g (9.88mmol) 3-benzyloxy-7-methoxynaphthalene-2-base amine and the mixture of 2.73g (19.8mmol) potassium carbonate in 20mLDMF.Mixture is stirred 2 hours in 60 DEG C, then in stirring at room temperature 16 hours.By in mixture impouring water, be extracted in EtOAc.Wash organic facies with water (3 ×), saturated NaCl (1 ×), use dried over sodium sulfate.Under reduced pressure except desolventizing, making residue crystallization from ethanol, obtain title compound, is pale solid,
Mp129-131 °.; NMR (CDCl): δ 7.50 (s, wide, 2H), (7.49 d, J=8.46Hz, 1H), 7.45-7.33 (m, 3H), 7.07 (s, 1H), 6.97 (d, J=2.20Hz, 1H), 6.89 (dd, J=8.82 and 2.57Hz, 1H), 6.62 (s, 1H), 5.20 (s, 3H), 4.05 (s, 2H), 3.88 (s, 3H), 3.80 (s, 3H) .MS (M+1): 352. analyze: CHNO: value of calculation C, 71.78; H, 6.02; N, 3.99. measured value C, 71.61; H, 5.86; N, 3.91.
Step 6
N-(tertbutyloxycarbonyl sulfamoyl)-N-(3-benzyloxy-7-methoxyl group naphthyl) glycine methyl ester
The solution of 649mg (8.76mmol) tert-butyl alcohol in 3mL dichloromethane is dripped in the solution of 1.24g (8.77mmol) Carbimide. chlorine sulfonyl ester in 25mL dichloromethane.By solution in stirring at room temperature 30 minutes, then drip 2.2g (6.26mmol) (3-benzyloxy-7-methoxynaphthalene-2-base is amino)-methyl acetate and the solution of 1.27g (12.6mmol) triethylamine in 25mL dichloromethane.By mixture in stirring at room temperature 90 minutes, then wash with water.Use dried over sodium sulfate organic facies, under reduced pressure except desolventizing.Residual oil thing uses hexane/ethyl acetate (70: 30) to carry out purification by flash chromatography, elutes title compound, is grease.
H-NMR (CDCl): δ 8.10 (s, 1H), 7.68 (s, wide, 1H), 7.54 (d, J=9.80Hz, 1H), 7.49-7.29 (m, 5H), 7.17 (s, 1H), 7.14-7.08 (m, 2H), 5.23 (s, 2H), 4.63 (s, 2H), 3.86 (s, 3H), 3.68 (s, 3H), 1.41 (s, 9H) .MS (M-1): 529.
Step 7
N-sulfamoyl-N-(3-benzyloxy-7-methoxyl group naphthyl) glycine methyl ester
By 3.1g (5.85mmol) N-(tertbutyloxycarbonyl sulfamoyl)-N-(3-benzyloxy-7-methoxyl group naphthyl) solution of glycine methyl ester in 40mL trifluoroacetic acid/dichloromethane (1: 1) in stirring at room temperature 30 minutes.Under reduced pressure except desolventizing.Joined by dichloromethane in residue, then under reduced pressure (4x) removing, obtaining oily solid, it ground together with ether (16 hours), obtain title compound, is solid,
Mp137-139 °; H-NMR (CDCl): δ 8.01 (s, 1H), 7.58 (d, J=8.83Hz, 1H), 7.51-7.32 (m5H), 7.23-7.05 (m, 3H), 5.17 (s, wide, 2H), 5.15 (s, 2H), 4.39 (s, 2H), 3.85 (s, 3H), 3.67 (s, 3H) .MS (M+1): 431. analyze: CHNOS: value of calculation C, 58.59; H, 5.15; N, 6.51. measured value C, 58.53; H, 5.05; N, 6.62.
Step 8
5-(3-benzyloxy-7-methoxynaphthalene-2-base)-1; 1-dioxo-[1; 2,5] thiadiazolidine-3-ketone potassium salt drips the solution of 4.4mL1.0M potassium tert-butoxide in THF in 1.89g (4.39mmol) N-sulfamoyl-N-(3-benzyloxy-7-methoxyl group naphthyl) solution of glycine methyl ester in 5mLTHF.By mixture in stirring at room temperature 18 hours.Filter the dense thick precipitation of gained, wash with the THF of small size.Drying under reduced pressure solid, obtains title compound, mp182-198 °.
Step 9
5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt
By 1.75g (4.01mmol) 5-(3-benzyloxy-7-methoxynaphthalene-2-base)-1, the 1-dioxo-solution of [1,2,5] thiadiazolidine-3-ketone potassium salt in 150mL water on 500mg10%Pd/C in 50psi hydrogenation 24 hours.Leach catalyst, with ethyl acetate washing containing filter liquor.By aqueous phase lyophilization, obtaining title compound, is light brown amorphous solid.
Mp260-265 ° of H-NMR (DMSO-d:7.90 (s, 1H), 7.54 (d, J=9.04Hz, 1H), 7.14 (s, 1H), 7.12 (d, J=2.64Hz, 1H), 6.98 (dd, J=9.04 and 2.64Hz, 1H), 4.20 (s, 2H), 3.81 (s, 3H) .MS (M-1): 307.
II.3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) propanoic acid
Steps A: (E)-3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) acrylic acid methyl ester..
To containing the bromo-2-(2' of 6-, 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane (165mg, 0.420mmol), Pd (dba) (7.68mg, 8.39 μm of ol), and add dioxane in the bottle of the nitrogen purging with Teflon nuts sealing of tri-butyl phosphine (3.39mg, 0.017mmol).Then, by syringe interpolation-cyclohexyl--methyl cyclohexylamine (90mg, 0.461mmol) and acrylic acid methyl ester. (0.076ml, 0.839mmol).At room temperature stir this mixture 12h.Then, this reactant mixture is poured in water (10mL), then use ether (2x10mL) to extract.The organic layer drying (MgSO4) that merges is concentrated.By HPLC (ISCO24g cylinder, 0 to 50%EA/Hex) purification gained residue to provide title compound.
1HNMR(500MHz，CDCl3)δ7.65(d，1H)，7.51-7.10(m，9H)，6.94(d，1H)，6.34(d，1H)，5.19(d，1H)，3.81(s，3H)，3.02(m，1H)，2.82(m，1H)，2.31(m，1H)，2.13(m，1H)，2.04(d，6H).
Step B:3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) methyl propionate.
To (E)-3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) acrylic acid methyl ester. (135mg, Pd (OH) (20%wt is added in EtOAc (2mL) solution 0.339mmol), 13mg, 0.019mmol).Purge this mixture and use hydrogen balloon (1atm) backfill.This mixture of strong agitation 1h in a hydrogen atmosphere.Then filter this reactant mixture by Celite and concentrate under vacuo.By HPLC (0 to 50%EA/Hex) purification gained residue to provide product.
1HNMR(500MHz，CDCl
3)δ7.52-7.41(m，2H)，7.24-7.12(m，5H)，7.00(d，1H)，6.98(s，1H)，6.87(d，1H)，5.12(d，1H)，3.72(s，3H)，3.00(m，1H)，2.91(t，2H)，2.80(dt，1H)，2.62(t，2H)2.25(m，1H)，2.12(m，1H)，2.08(d，6H).
Step C:3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) propanoic acid.
To 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) the THF/MeOH/ water (1:1:1 of methyl propionate (120mg, 0.30mmol), 1.5mL) add LiOH (72mg, 3.0mmol) in solution.Then on heat block, this reaction is heated to 60 DEG C.After 12h, this reaction poured into 1NHCl (10mL) and extract with EtOAc (2x10mL).The organic layer drying (MgSO) that merges is concentrated.By HPLC (ISCO, 24g, 0 to 50%MeOH/DCM) purification gained residue to provide product.
1HNMR(500MHz，CDCl
3)δ7.47(m，2H)，7.24-7.12(m，5H)，7.00(m，2H)，6.90(d，1H)，5.14(d，1H)，3.01(m，1H)，2.95(t，2H)，2.80(dt，1H)，2.70(t，2H)，2.24(m，1H)，2.15(m，1H)，2.04(d，6H).
By the component I for preparing and II, obtain described diabetes combination of oral medication according to following dosage is composite:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 15mg
(2) 3-(2-(2', 6'-dimethyl-[1,1'-the biphenyl]-3-base) chromane-6-base) propanoic acid of 30mg
(3) 268mg microcrystalline Cellulose,
(4) 20mg cross-linking sodium carboxymethyl cellulose, and
(5) 5mg magnesium stearate.
The bull C57BLob/ob mice in 11 week age is housed in reverse smooth circular chamber (from 6:00p.m. to 6:00a.m. illumination) with 6/cage, arbitrarily edible Purina Rodent Meal and drinking-water.At the 1st day, get tail blood sample at 8:00am, measure plasma glucose levels.Animal is randomized into matched group and compound group.The meansigma methods of the plasma glucose levels of each group is mated.Then the Orally administered solvent of animal (there is 0.5% carboxymethyl cellulose of 0.2% tween 80) or the compound (30mg/kg) in solvent is given.Every day, to mice administration, amounts to 3 days.At the 4th day, get basal blood specimens.Adopt the concentration of glucose of YSI2700 dual pathways biochemistry analyzer (YellowSpringsInstrumentCo., YellowSprings, OH) analysed for plasma sample, adopt ELISA algoscopy to measure insulin concentration.Test result shows, its concentration of glucose is 80-120mg/dL, its insulin concentration: 4.4 ~ 8.0mmol/L.
Comparative example 1
Containing the component I of 100mg, not containing component I I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 2
Containing the component I of 50mg, not containing component I I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Comparative example 3
Containing the component I I of 100mg, not containing component I, all the other conditions are constant, and its concentration of glucose and insulin concentration are all in the scope of embodiment 1.
Comparative example 4
Containing the component I I of 50mg, not containing component I, all the other conditions are constant, and its concentration of glucose is greater than 150mg/dL.
Above-described embodiment and comparative example explanation, diabetes combination of oral medication of the present invention, it is composite by two kinds of dissimilar active matters, under the prerequisite reaching identical therapeutic effect, the use amount of the active matter of medicine is reduced at least 1/2, when two kinds of active matters that the present invention adopts are used alone, within the scope of equal volume, glucose in blood cannot be reduced in normal range of the present invention, prove to create cooperative effect between two kinds of active matters that the present invention adopts.
Applicant states, the present invention illustrates diabetes combination of oral medication of the present invention by above-described embodiment, but the present invention is not limited to above-mentioned specific components and formula, does not namely mean that the present invention must rely on above-mentioned detailed component and formula could be implemented.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of each raw material of product of the present invention, all drops within protection scope of the present invention and open scope.
Claims (2)
1. a diabetes combination of oral medication, it comprises following component:
(1) 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] thiadiazolidine-3-ketone potassium salt of 10-20mg
(2) 3-(2-(2', 6'-dimethyl-[1,1'-the biphenyl]-3-base) chromane-6-base) propanoic acid of 20-30mg
(3) 200-300mg microcrystalline Cellulose,
(4) 10-25mg cross-linking sodium carboxymethyl cellulose, and
(5) 1-8mg magnesium stearate.
2. diabetes combination of oral medication as claimed in claim 1, it is characterized in that, described 5-(3-hydroxyl-7-methoxynaphthalene-2-base)-1,1-dioxo-[1,2,5] ratio of thiadiazolidine-3-ketone potassium salt and 3-(2-(2', 6'-dimethyl-[1,1'-biphenyl]-3-base) chromane-6-base) propanoic acid is less than in 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510766787.7A CN105287535A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetes oral pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510766787.7A CN105287535A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetes oral pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287535A true CN105287535A (en) | 2016-02-03 |
Family
ID=55185825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510766787.7A Pending CN105287535A (en) | 2015-11-11 | 2015-11-11 | Anti-diabetes oral pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287535A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101014598A (en) * | 2004-06-21 | 2007-08-08 | 默克公司 | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
-
2015
- 2015-11-11 CN CN201510766787.7A patent/CN105287535A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101014598A (en) * | 2004-06-21 | 2007-08-08 | 默克公司 | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| CN101687828A (en) * | 2007-06-04 | 2010-03-31 | 诺瓦提斯公司 | Thiadiazole derivatives as antidiabetic agents |
| CN104994848A (en) * | 2013-02-22 | 2015-10-21 | 默沙东公司 | Antidiabetic bicyclic compounds |
Non-Patent Citations (1)
| Title |
|---|
| 万祺等: "治疗2型糖尿病新靶标及新先导化合物的研究进展", 《中国新药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60225561T2 (en) | INDANIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES AND METHOD OF PREPARING THEM | |
| CN103415519B (en) | As 6,7-dihydro-pyrazol [1, the 5-a] pyrazine-4-yl amine derivatives that beta-secretase (BACE) inhibitor is useful | |
| TW201121544A (en) | Novel phenol derivative | |
| TW201043226A (en) | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | |
| CN105287535A (en) | Anti-diabetes oral pharmaceutical composition | |
| CN105412095A (en) | Anti-diabetes oral drug composition | |
| CN105213384A (en) | A kind of diabetes combination of oral medication | |
| CN105213381A (en) | A kind of diabetes combination of oral medication | |
| CN105213383A (en) | A kind of diabetes combination of oral medication | |
| CN105232552A (en) | Anti-diabetic oral drug composition | |
| CN105434433A (en) | Antidiabetic oral drug composition | |
| CN105213382A (en) | A kind of diabetes combination of oral medication | |
| CN105213387A (en) | A kind of diabetes combination of oral medication | |
| CN105213385A (en) | A kind of diabetes combination of oral medication | |
| CN105213379A (en) | A kind of diabetes combination of oral medication | |
| CN105232545A (en) | Antidiabetic oral drug composition | |
| CN105520943A (en) | Anti-diabetics oral pharmaceutical composition | |
| CN105193797A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105193796A (en) | Diabetes mellitus resistant oral medicine composition | |
| CN105434434A (en) | Antidiabetic oral drug composition | |
| CA3038382C (en) | Substituted phenylpropionic acid enantiomer and manufacturing method, composition, and application of same | |
| CN103012314B (en) | Sulfonamide compound and preparation method as well as application thereof | |
| CN105232546A (en) | Anti-diabetic oral drug composition | |
| CN105287531A (en) | Anti-diabetic orally-administered pharmaceutical composition | |
| CN105213386A (en) | A kind of diabetes combination of oral medication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |
|
| WD01 | Invention patent application deemed withdrawn after publication |